Know Cancer

forgot password

A Phase I Study of MK-2206 in Combination With Trastuzumab and Lapatinib in HER2-Positive Breast and Gastric Cancer

Phase 1
18 Years
Open (Enrolling)
Adenocarcinoma of the Gastroesophageal Junction, HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Recurrent Esophageal Cancer, Recurrent Gastric Cancer, Stage IIIC Breast Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer, Stage IV Breast Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer

Thank you

Trial Information

A Phase I Study of MK-2206 in Combination With Trastuzumab and Lapatinib in HER2-Positive Breast and Gastric Cancer


I. To define maximum tolerated dose (MTD) and the dose-limiting toxicities (DLT) of MK-2206
(Akt inhibitor MK2206) in combination with trastuzumab and lapatinib (lapatinib ditosylate)
in adult patients with locally advanced or metastatic HER2-positive breast or gastric
cancer; two schedules of lapatinib administration will be examined-continuous daily dosing
and pulsatile dosing.


I. To provide preliminary assessment of the safety and tolerability of MK-2206 administered
in combination with epidermal growth factor receptor (EGFR)/HER2 blockade via trastuzumab
and lapatinib in adult patients with a locally advanced or metastatic HER2-positive breast
or gastric tumor.

II. To explore the anti-tumor activity of MK-2206 in combination with trastuzumab and
lapatinib in patients with advanced HER2-positive solid tumor.


I. To correlate the anti-tumor activity of MK-2206 in combination with trastuzumab and
lapatinib in HER2-positive solid tumor patients with phosphoinositide 3-kinase (PI3K)
pathway activation events, e.g., phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic
subunit alpha (PIK3CA) or phosphatase and tensin homolog (PTEN) and other related gene
mutations and expressions; to compare the HER2 and PI3K-PTEN mutation status of the primary
tumor to metastatic tumor biopsy when available.

OUTLINE: This is a dose-escalation study of Akt inhibitor MK2206 and lapatinib ditosylate.

Patients receive Akt inhibitor MK2206 orally (PO) on days 1, 8, and 15; lapatinib ditosylate
PO once daily (QD) on days 1-21 or on days 1-3, 8-10, and 15-17; and trastuzumab
intravenously (IV) over 30-90 minutes on day 1. Courses repeat every 21 days in the absence
of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 4 weeks.

Inclusion Criteria:

- Patients must have histologically confirmed HER2-positive invasive breast, gastric,
or gastroesophageal carcinoma that is locally advanced and unresectable or metastatic
and for which standard curative or palliative measures do not exist or are no longer
effective; HER2-positive is defined as HER2 overexpression and/or amplification as
determined by immunohistochemistry (3+) or fluorescence in situ hybridization (FISH)
(>= 2.0)

- Patients must have measurable disease, defined as at least one lesion that can be
accurately measured in at least one dimension (longest diameter to be recorded for
non-nodal lesions and short axis for nodal lesions) as >= 20 mm with conventional
techniques or as >= 10 mm with spiral computed tomography (CT) scan

- Patients may have previously received trastuzumab or lapatinib as part of a regimen
in the adjuvant or metastatic setting with evidence of progression

- No restriction on prior chemotherapy regimens for advanced stage disease; no
restriction for prior hormonal therapy

- Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)

- Life expectancy of greater than three months

- Left ventricular ejection fraction (LVEF) by multi-gated radionuclide angiography
scan (MUGA) or echocardiogram (ECHO) at or above the lower limit of normal of 50%

- Leukocytes >= 3,000/mcL

- Absolute neutrophil count >= 1,000/mcL

- Platelets >= 100,000/mcL

- Total bilirubin within normal institutional limits

- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
[SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT])
=< 2.5 X institutional upper limit of normal

- Creatinine within normal institutional limits OR creatinine clearance >= 60
mL/min/1.73 m^2 for patients with creatinine levels above institutional normal

- The effects of MK-2206 on the developing human fetus are unknown; for this reason,
women of child-bearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control; abstinence) prior to study entry and
for the duration of study participation; should a woman become pregnant or suspect
she is pregnant while she or her partner is participating in this study, she should
inform her treating physician immediately

- Patients must be able to swallow whole tablets; nasogastric or gastrostomy (G) tube
administration is not allowed; tablets must not be crushed or chewed

- Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for
nitrosoureas or mitomycin C) prior to entering the study or those who have not
recovered from adverse events due to agents administered more than 4 weeks earlier;
if the patient has residual toxicity from prior treatment, toxicity must be =< grade

- Patients who are receiving any other investigational agents; no concurrent use of
endocrine therapy is permitted; patients on bisphosphonates or denosumab for bone
metastases or osteopenia/porosis are considered eligible

- Patients with active brain metastases requiring radiation should be excluded as they
may develop progressive neurologic dysfunction that would confound the evaluation of
neurologic and other adverse events; patients with stable brain metastases (mets) (>
6 months without change in steroids or seizure medications) will be considered

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to MK-2206, trastuzumab, or lapatinib

- Patients receiving any medications or substances that are inhibitors or inducers of
cytochrome P450 3A4 (CYP450 3A4) are ineligible

- Preclinical studies demonstrated the potential of MK-2206 for induction of
hyperglycemia in all preclinical species tested; patients with diabetes or in risk
for hyperglycemia should not be excluded from trials with MK-2206, but the
hyperglycemia should be well controlled on oral agents or insulin before the patient
enters the trial; patients with poorly controlled diabetes with hemoglobin (Hgb)A1C >
9% will be excluded

- Preclinical studies indicated transient changes in corrected QT interval (QTc)
interval during MK-2206 treatment; prolongation of QTc interval is potentially a
safety concern while on MK-2206 therapy; cardiovascular baseline QTc > 480 msec will
exclude patients from entry on study

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- Pregnant women are excluded from this study because MK-2206 an agent with the
potential for teratogenic or abortifacient effects; because there is an unknown but
potential risk for adverse events in nursing infants secondary to treatment of the
mother with MK-2206, breastfeeding should be discontinued if the mother is treated
with MK-2206; these potential risks may also apply to other agents used in this study

- Patients with unstable angina, congestive heart failure, or with a history of a
myocardial infarction within 6 months; patients with high-risk uncontrolled
arrhythmias (ventricular tachycardia, high-grade atrioventricular [AV] block,
supraventricular arrhythmias which are not adequately rate-controlled); patients with
uncontrolled hypertension (i.e., over 160/90 mmHg); patients who are controlled on
anti-hypertensive medication will be allowed to enter the study

- Patients known to be human immunodeficiency virus (HIV)-positive and are on
combination antiretroviral therapy are ineligible because of the potential for
pharmacokinetic interactions with MK-2206; in addition, these patients are at
increased risk of lethal infections when treated with marrow-suppressive therapy and
as such patients with cluster of differentiation (CD)4 counts < 200 will be excluded;
HIV-positive patients not on anti-retrovirals and with an adequate CD4 count will be
considered eligible

Type of Study:


Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

MTD of Akt inhibitor MK-2206 and lapatinib ditosylate in combination with trastuzumab determined by dose limiting toxicities as measured by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4

Outcome Description:

Described by frequency and grade, by course and over all courses, with the maximum grade over all courses used as the summary measure per patient.

Outcome Time Frame:

21 days

Safety Issue:


Principal Investigator

Devika Gajria

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center


United States: Food and Drug Administration

Study ID:




Start Date:

September 2012

Completion Date:

Related Keywords:

  • Adenocarcinoma of the Gastroesophageal Junction
  • HER2-positive Breast Cancer
  • Male Breast Cancer
  • Recurrent Breast Cancer
  • Recurrent Esophageal Cancer
  • Recurrent Gastric Cancer
  • Stage IIIC Breast Cancer
  • Stage IIIC Esophageal Cancer
  • Stage IIIC Gastric Cancer
  • Stage IV Breast Cancer
  • Stage IV Esophageal Cancer
  • Stage IV Gastric Cancer
  • Adenocarcinoma
  • Adenocarcinoma, Mucinous
  • Breast Neoplasms
  • Esophageal Diseases
  • Esophageal Neoplasms
  • Stomach Neoplasms
  • Breast Neoplasms, Male



Memorial Sloan Kettering Cancer Center New York, New York  10021